For evaluation of entinostat monotherapy, models CTG-1008 (Fig. 4F) and CTG-1916 (Fig. 5F) had no single agent activity in line with previously-published studies showing that PAX3::FOXO1 is dispensable for tumor maintenance in the short term4,19,20. The gene discussed is PAX3; the disease is neoplasm.